<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148900</url>
  </required_header>
  <id_info>
    <org_study_id>79135</org_study_id>
    <nct_id>NCT02148900</nct_id>
  </id_info>
  <brief_title>Development of a Blood Test for Marfan Syndrome</brief_title>
  <official_title>Development of a Blood Test for Marfan Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shriners Hospitals for Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether a simple blood test can be a useful
      clinical tool for monitoring aortic disease in Marfan syndrome and Marfan-related disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine whether increased quantitites of
      circulating microfibril fragments, measured with a simple blood test, are associated with
      aortic root size and increased growth of the aortic root in Marfan syndrome and related
      disorders. The secondary objectives of this study are to: (1) Determine a Marfan &quot;signature&quot;
      profile of circulating microfibril fragments. (2) Determine if high concentrations of
      fibrillin-1 fragments are associated with large aortic root diameters. (3) Determine which
      fibrillin-1 fragments are good biomarkers for aortic root growth and size in Marfan syndrome.
      (4) Determine the relation between fibrillin-1, aortic root diameter, and medical and
      lifestyle factors reported on questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>microfibril fragments</measure>
    <time_frame>measured yearly over 5 years</time_frame>
    <description>Plasma will be tested using sandwich ELISAs and standard curves to quantitate fragments of fibrillin-1, fibrillin-2, and fibulin-4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aortic root growth</measure>
    <time_frame>yearly for five years</time_frame>
    <description>Aortic root growth will be correlated with concentrations of circulating microfibril fragments.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>medical and lifestyle issues</measure>
    <time_frame>yearly for five years</time_frame>
    <description>Information from questionnaires will be associated with aortic root growth and concentrations of circulating microfibril fragments.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Marfan Syndrome</condition>
  <condition>Marfan Related Disorders</condition>
  <condition>Control Subjects</condition>
  <arm_group>
    <arm_group_label>Marfan</arm_group_label>
    <description>Diagnosis of Marfan syndrome, according to Ghent criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marfan Related Disorders</arm_group_label>
    <description>Diagnosis of Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Familial Thoracic Aortic Aneurysm and Dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Subjects</arm_group_label>
    <description>Unaffected by Marfan or Marfan related disorders.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma Frozen Cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes 3 groups: (1) individuals with Marfan syndrome; (2)
        individuals with Marfan-related disorders; (3) unaffected controls. Both genders, ages 4 to
        26, will be included. Geographic locations will include the Pacific Northwest, Texas, and
        the Salt Lake City/Denver areas.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 4-26 years of age for all participants

          -  Diagnosis of Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome,
             or Familial Thoracic Aortic Aneurysm and Dissection for inclusion in Marfan and
             Marfan-related disorders groups

          -  Diagnosis of unaffected by Marfan syndrome and Marfan-related disorders for inclusion
             in control group

          -  Able and willing to sign informed consent/assent

          -  Signed HIPPA compliant research authorization

        Exclusion Criteria:

          -  Other known cardiovascular disorder for unaffected controls
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Y. Sakai, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shriners Hospitals for Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn Y. Sakai, Ph.D.</last_name>
    <phone>503-221-3436</phone>
    <email>lys@shcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Sienko, Ph.D.</last_name>
    <phone>503-221-3481</phone>
    <email>sst@shcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lurie Childrens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Van't Hof</last_name>
      <phone>312-227-1549</phone>
      <email>kvanthof@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Camarda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Yetman, MD</last_name>
      <phone>402-955-4322</phone>
      <email>ayetman@childrensomaha.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Warta</last_name>
      <phone>402-559-6256</phone>
      <email>sara.warta@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Yetman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Holmes, MD, MPH</last_name>
      <phone>503-494-4305</phone>
      <email>holmesk@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Abigail Hata, MS</last_name>
      <phone>503-418-1061</phone>
      <email>hata@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathyn Holmes, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Y. Sakai, Ph.D.</last_name>
      <phone>503-221-3436</phone>
      <email>lys@shcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Susan Sienko, Ph.D.</last_name>
      <phone>503-221-3481</phone>
      <email>sst@shcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lynn Y. Sakai, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline T. Hecht, Ph.D.</last_name>
      <phone>713-500-5764</phone>
      <email>jacqueline.t.hecht@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elena Serna</last_name>
      <phone>713-500-5785</phone>
      <email>maria.e.serna@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jacqueline T. Hecht, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shriners Hospitals for Children</investigator_affiliation>
    <investigator_full_name>Lynn Y. Sakai, Ph.D.</investigator_full_name>
    <investigator_title>Sr. Investigator</investigator_title>
  </responsible_party>
  <keyword>Marfan syndrome</keyword>
  <keyword>blood test</keyword>
  <keyword>aortic root size</keyword>
  <keyword>Marfan related disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

